Want to see CNTB full AI Analyst Report?
CNTB Stock Chart & Stats
$2.14
-$0.06(-2.73%)
At close: 4:00 PM EDT
$2.14
-$0.06(-2.73%)
Day’s Range― - ―
52-Week Range$1.23 - $3.82
Previous CloseN/A
Volume327.99K
Average Volume (3M)97.97K
Market Cap
$130.96M
Enterprise Value$102.81
Total Cash (Recent Filing)$44.34M
Total Debt (Recent Filing)$690.00K
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Sep 15, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding62,963,852
10 Day Avg. Volume111,495
30 Day Avg. Volume97,966
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.74
Price to Sales (P/S)2452.52
P/FCF Ratio-3.04
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.29Price Target Upside240.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-7.45
Revenue Forecast (FY)$34.24M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet StrengthMinimal debt materially reduces interest expense and bankruptcy risk for a cash-burning clinical-stage biotech. Low leverage preserves flexibility to fund R&D, pursue partnerships, or access capital on better terms, supporting the firm's ability to advance trials without heavy debt servicing.
Constructive Clinical ProgressConsistent, positive clinical signals and an absence of safety issues are structural de-risking events for a development-stage biopharma. They improve the odds of later-stage success, enhance partnering or licensing appeal, and can unlock milestone payments or regulatory pathways over the medium term.
Extended Runway Via FinancingA committed $20.2M private placement that extends runway into H2 2027 provides durable operational breathing room. That extra time reduces immediate refinancing pressure, allowing management to reach additional clinical inflection points that could materially change capital needs or partnership leverage.
Bears Say
Zero And Volatile RevenueThe company's revenue profile is inconsistent and currently nil, reflecting no marketed products and reliance on irregular collaboration payments. Without durable product sales, revenue unpredictability forces dependence on financing or deals, limiting self-sustaining growth prospects over the medium term.
Large Persistent Cash BurnSustained negative operating and free cash flow erodes liquidity and necessitates repeated external funding to continue clinical programs. Persistent cash burn compresses strategic options, increases dilution risk from future raises, and makes long-term planning contingent on successful milestone or financing execution.
Eroding Equity And Asset BaseMaterial declines in equity and assets reduce financial cushions against adverse outcomes and shrink borrowing or partnership leverage. A weakened capital base increases the likelihood that future funding will be more dilutive or restrictive, amplifying long-term financing and solvency risk if clinical progress stalls.
Connect Biopharma Holdings News
CNTB FAQ
What was Connect Biopharma Holdings’s price range in the past 12 months?
Connect Biopharma Holdings lowest stock price was $1.23 and its highest was $3.82 in the past 12 months.
What is Connect Biopharma Holdings’s market cap?
Connect Biopharma Holdings’s market cap is $130.96M.
When is Connect Biopharma Holdings’s upcoming earnings report date?
Connect Biopharma Holdings’s upcoming earnings report date is Sep 15, 2026 which is in 46 days.
How were Connect Biopharma Holdings’s earnings last quarter?
Connect Biopharma Holdings released its earnings results on May 12, 2026. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Connect Biopharma Holdings overvalued?
According to Wall Street analysts Connect Biopharma Holdings’s price is currently Undervalued.
Does Connect Biopharma Holdings pay dividends?
Connect Biopharma Holdings does not currently pay dividends.
What is Connect Biopharma Holdings’s EPS estimate?
Connect Biopharma Holdings’s EPS estimate is -0.32.
How many shares outstanding does Connect Biopharma Holdings have?
Connect Biopharma Holdings has 62,963,852 shares outstanding.
What happened to Connect Biopharma Holdings’s price movement after its last earnings report?
Connect Biopharma Holdings reported an EPS of $0.05 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 14.53%.
Which hedge fund is a major shareholder of Connect Biopharma Holdings?
Currently, no hedge funds are holding shares in CNTB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Connect Biopharma Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.29 (240.45% Upside)
$7.29 (240.45% Upside)
Insider Transactions
Bought Shares
Worth $370.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.19%
Trailing 12-Months
Company Description
Connect Biopharma Holdings
Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.
CNTB Stock 12 Month Forecast
Average Price Target
$7.29
▲(240.45% Upside)
Technical Analysis
Scinai Immunotherapeutics
―
GT Biopharma
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
21.30% Insiders
0.04% Mutual Funds
0.09% Other Institutional Investors
77.12% Public Companies and
Individual Investors